Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Autor: Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Mortier, Laurent, Dereure, Olivier, Lebbe, Céleste, Mansard, Sandrine, Grange, Florent, Neidhardt, Eve-Marie, Lesimple, Thierry, Machet, Laurent, Bedane, Christophe, Maillard, Hervé, Dalac-Rat, Sophie, Nardin, Charlée, Szenik, Alexandra, Denden, Amine, Dutriaux, Caroline
Zdroj: In European Journal of Cancer September 2021 154:57-65
Databáze: ScienceDirect
Externí odkaz: